5-(furan-2-yl)-N-[3-(1H-imidazol-1-yl)propyl]-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 5-(furan-2-yl)-N-[3-(1H-imidazol-1-yl)propyl]-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
• 英文别名: 5-(furan-2-yl)-N-(3-imidazol-1-ylpropyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
• 化学式: C₁₈H₁₅F₃N₆O₂
• 分子量: 404.3
• InChiKey: XCOWKOTZQYHOAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  90.2
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• SMALL MOLECULE INHIBITORS FOR MRP1 AND OTHER MULTIDRUG TRANSPORTERS
  申请人：THE CLEVELAND CLINIC FOUNDATION

  公开号：EP1753422B1

  公开（公告）日：2008-05-28
• Small Molecule Inhibitors of Mrp1 and Other Multidrug Transporters
  申请人：Gudkov Andrei

  公开号：US20080032966A1

  公开（公告）日：2008-02-07

  A method of potentiating the activity of a therapeutic drug, like a chemotherapeutic drug or an antibiotic, in a cell or tissue, by inhibiting the efflux capability of a multidrug transporter are disclosed. The method is useful in the treatment of a cancer by sensitizing tumor cells to a chemotherapeutic agent. Compounds capable of inhibiting an efflux capability of a multidrug transporter also are disclosed.
• US8318724B2
  申请人：——

  公开号：US8318724B2

  公开（公告）日：2012-11-27
• [EN] COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE TROUBLES NEURODÉGÉNÉRATIFS ET MÉTABOLIQUES
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2020232255A1

  公开（公告）日：2020-11-19

  Compounds described herein may be used for the treatment of neurodegenerative diseases linked to protein misfolding, including prion diseases, Alzheimers' disease, Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), and also other neurodegenerative, degenerative, metabolic and ischemic conditions. Indeed, NAD metabolism impairment is also a critical feature in brain ischemia/reperfusion injury, Wallerian degeneration, kidney failure, multiple sclerosis, aging, and metabolic disorders such as diabetes mellitus. Therapies that elevate or stabilize NAD levels may thus have broad potential for treating many severely debilitating neurological and metabolic conditions. Evidence is provided herein with compounds from 8 lead series for NAD restoring properties and for therapeutic efficacy in cellular and/or animal models of prion disease, PD and ALS.